



The Most Trusted Source of BioProcess Technology®

## 4th Annual Conference



# BioProcess Technology Amsterdam

April 2-4, 2007

*Development and Production of  
Antibodies, Vaccines, and Gene Vectors*

Please join us as we explore the problems faced while taking cell-derived products through development and into large-scale production.

This meeting will showcase the industry's more successful efforts as we focus on trends in facility design and regulatory practices, plus recent advances in cell culture, analytical, and purification methods. Posters and workshops will then be used to supplement the program with details on the vital technologies and services needed for success.

**Sponsored By:**



**Topics:**

- Cell Engineering
- Scale-Up
- Media and Assay Development
- Feed and Harvest Strategies
- Purification
- Safety and Regulatory Issues
- Characterization and Comparability

**Applications:**

- Antibodies
- Recombinant Proteins
- Viral Vaccines
- Viral Gene Vectors
- Cellular Therapies





# BioProcess Technology-Amsterdam

**Development and Production of Antibodies, Vaccines, and Gene Vectors**

## SUNDAY, APRIL 1, 2007

4:00-6:00 pm **Registration and Welcome Reception**

## MONDAY, APRIL 2, 2007

7:00-8:00 am **Registration, Continental Breakfast — Meeting Room Foyer**

8:00-8:30 am **Introduction**  
Keith L. Carson – *Conference Chairman*

8:30-9:15 am **Production, Inactivation and Purification of a BSL-3 Class Viral Vaccine**  
Marcel de Vocht, Ph.D. – *Crucell Corporation*

9:15-10:00 am **Lentiviral Vectors: Research and Therapeutic Applications**  
Boro Dropulic, Ph.D. – *Lentigen Corporation*

10:00-10:30 am **Break — Meeting Room Foyer**

10:30-11:15 am **AAV1-Mediated Gene Therapy for Lipoprotein Lipase Deficiency**  
Janneke Meulenberg, Ph.D. – *Amsterdam Molecular Therapeutics*

1:15-Noon **Analysis and Optimization of Monoclonal Antibody Production Facilities with Simulation and Scheduling Tools**  
Victor Papavasileiou – *Intelligen, Inc.*  
(co-authored Demetri Petrides - *Intelligen, Inc.* and co-presented by Marc Hulst - *Centocor BV Leiden*)

Noon-1:30 pm **Lunch and Poster Session — Meeting Room Foyer**

1:30-2:15 pm **Mini Bioreactors for Screening in Bioprocess Development**  
Francesc Godia Casablanacas, Ph.D. – *University Autònoma de Barcelona*

2:15-3:00 pm **Cell Line Engineering and Characterization for Production of High Titer HIV-1 Based Lentiviral Vector**  
Yajin Ni, M.D., Ph.D. – *VIRxSYS Corporation*

3:00-3:30 pm **Break — Exhibit Area**

3:30-4:15 pm **Development of a Process for Cell Culture Production of a Cold-Adapted Live Attenuated Influenza Vaccine (LAIV)**  
Richard Schwartz, Ph.D. – *MedImmune Vaccines*

4:15-5:00 pm **Closing the Manufacturing Process for Dendritic Cell Vaccines**  
James Talmadge, Ph.D. – *University of Nebraska Medical Center*

5:00-5:45 pm **Toolbox of Human Glyco-Engineered Cell Lines with the Feature of Controlling Antibody Glycosylation**  
Hans Baumeister, Ph.D. – *GLYCOTOPE GmbH*

6:00-7:30 pm **Reception — Meeting Room Foyer**

*Continued on page 2*



## TUESDAY, APRIL 3, 2007

- 7:30-8:30 am **Breakfast — Meeting Room Foyer**
- 8:30-9:15 am **Rapid Analytical Tools to Support Bioprocess Development, In-Process Controls and Release**  
Bruce Compton, Ph.D. – *CMC Biopharmaceuticals A/S*
- 9:15-10:00 am **High-Titre, Stable Cell Lines Using Novel Synthetic Genetic Elements**  
Igor Fisch, Ph.D. – *Selexis SA*
- 10:00-10:30 am **Break — Meeting Room Foyer**
- 10:30-11:15 am **Model-Based Development and Optimization of Protein Separations**  
Christian Frech, Ph.D. - *Hochschule Mannheim Institut*
- 11:15-Noon **Non-Replicating Adenovirus-Vectored Bird Flu Vaccine for Mass-Immunization of Both Humans and Birds**  
De-chu Tang, Ph.D. – *Vaxin, Inc.*
- Noon-6:00 pm **Free Afternoon with Recommended Activities**
- 6:00-9:00 pm **Conference Banquet**

## WEDNESDAY, APRIL 4, 2007

- 7:30-8:30 am **Breakfast — Meeting Room Foyer**
- 8:30-9:15 am **Merck Technical Workshops**
- 9:15-10:00 am **A Process Contaminant Becomes the Product: Discovery of Seneca Valley Virus, a Systemically Deliverable Oncolytic Picornavirus for the Treatment of Patients with Solid Tumors with Neuroendocrine Features**  
Paul Hallenbeck, Ph.D – *Neotropix, Inc.*
- 10:00-10:30 am **Break — Meeting Room Foyer**
- 10:30-11:15 am **Scouting for Optimized Protein Purification with the Protein-Purification-Parameter-Screening System**  
Hartmut Schlüter, Ph.D. - *Charité - University Medicine Berlin*
- 11:15-Noon **Cell Line Development and Culture Scale-Up - A Strategy for Accelerating Antibody Development**  
Abdul Wajid, Ph.D. – *XOMA Corporation (US) LLC*
- Noon-1:30 pm **Lunch and Poster Session — Meeting Room Foyer**
- 1:30-2:15 pm **Plasmid DNA Vaccines from R&D to Manufacturing, A Scale-Up Story**  
Emmanuel Macedo, Ph.D. – *GE Healthcare*
- 2:15-3:00 pm **Production of Antibodies and Vaccines by a Novel Bioprocess Platform**  
Dorsey Stuart, Ph.D. – *Neugenesis Corporation*
- 3:00-3:30 pm **Break — Meeting Room Foyer**
- 3:30-4:15 pm **Designed Protein Storage Organelles: A New Approach for Engineered Protein Expression in Eukaryotic Cells**  
Kevin O' Connor, Ph.D. – *ERA Biotech*
- 4:15-5:00 pm **Process Economy of Disposable Chromatography in Antibody Manufacturing**  
Klaus Tarrach – *Sartorius AG*